Bausch Health Reports Strong Q1 2026 Earnings with Reaffirmed Guidance
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Apr 30 2026
0mins
Should l Buy BHC?
Source: seekingalpha
- Consistent Growth: Bausch Health reported Q1 2026 revenue of $2.524 billion, a 12% year-over-year increase, with adjusted EBITDA at $837 million, demonstrating a robust performance across 12 consecutive quarters, reflecting effective strategies in core business execution and R&D innovation.
- Strong Salix Performance: The Salix division generated $639 million in revenue, with Xifaxan showing a remarkable 21% year-over-year growth in IBS-D and OHE markets, enhancing the company's competitive position in the gastrointestinal drug sector and increasing market share.
- Solta's Success in China: Solta Medical achieved $171 million in revenue, with a staggering 193% year-over-year growth in China, indicating strong post-integration demand and solidifying the company's leadership in the global market.
- 2026 Outlook: The company reaffirmed its 2026 revenue guidance between $5.250 billion and $5.400 billion, with adjusted EBITDA projected between $2.875 billion and $2.950 billion, showing optimism despite the anticipated impact of new tariffs, reflecting a proactive approach to market changes.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy BHC?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on BHC
Wall Street analysts forecast BHC stock price to rise
4 Analyst Rating
0 Buy
4 Hold
0 Sell
Hold
Current: 5.730
Low
7.00
Averages
8.25
High
10.00
Current: 5.730
Low
7.00
Averages
8.25
High
10.00
About BHC
Bausch Health Companies Inc. is a global, diversified pharmaceutical company. The Salix segment includes sales in the U.S. of GI products. The International segment includes sales of Bausch + Lomb products and Solta Medical aesthetic medical devices, outside the U.S. and Puerto Rico of branded pharmaceutical products, branded generic pharmaceutical products and OTC products. The Solta Medical segment includes global sales of Solta Medical aesthetic medical devices. The Diversified segment includes sales in the U.S. of pharmaceutical products in the areas of neurology and certain other therapeutic classes, dermatology products, generic pharmaceutical products and dentistry products. The Bausch + Lomb segment includes global sales of Bausch + Lomb Vision Care, Surgical and Pharmaceuticals products. Its drug candidate, Larsucosterol binds to and inhibits the activity of DNA methyltransferases, epigenetic enzymes that are elevated and associated with hypermethylation found in AH patients.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Bausch Health Companies Reports Strong Q1 Earnings, Exceeds Estimates
- Significant Revenue Growth: Bausch Health Companies reported Q1 revenue of $2.52 billion, a 12% year-over-year increase, primarily driven by its Bausch + Lomb eyecare segment, which generated $1.24 billion, reflecting a 9% gain.
- Substantial Net Income Increase: The company's non-GAAP net income surged by 35% to $296 million, translating to $0.78 per share, surpassing analyst expectations of $0.68, indicating enhanced profitability.
- Consistent Growth Indicator: Bausch has achieved 12 consecutive quarters of year-over-year revenue growth, demonstrating stability and execution within its operations, despite its somewhat sprawling business structure.
- 2026 Financial Outlook: The company maintained its full-year 2026 revenue guidance of $10.67 billion to $10.92 billion, with adjusted EBITDA expected to be between $3.89 billion and $4.01 billion, reflecting confidence in future growth.
See More
Bausch Health Beats Q1 Estimates with Strong Revenue Growth
- Significant Revenue Growth: Bausch Health reported Q1 revenue of $2.52 billion, a 12% year-over-year increase that surpassed analyst expectations of $2.42 billion, driven primarily by a strong performance in its Bausch + Lomb eyecare segment, which contributed a 9% gain.
- Substantial Net Income Increase: The company's non-GAAP net income surged by 35% to $296 million, translating to $0.78 per share, reflecting successful cost control and operational efficiency, which bolsters investor confidence in the company's financial health.
- Sustained Growth Strategy: Bausch Health has achieved 12 consecutive quarters of year-over-year revenue growth, indicating stability and execution capability despite its sprawling business structure, which may continue to attract investor interest moving forward.
- Stable Outlook: The company maintained its full-year 2026 revenue guidance of $10.67 billion to $10.92 billion, with adjusted EBITDA expected to be between $3.89 billion and $4.01 billion, demonstrating management's confidence in future performance, although no profitability guidance was provided.
See More
Bausch Health Reports Strong Q1 2026 Earnings with Reaffirmed Guidance
- Consistent Growth: Bausch Health reported Q1 2026 revenue of $2.524 billion, a 12% year-over-year increase, with adjusted EBITDA at $837 million, demonstrating a robust performance across 12 consecutive quarters, reflecting effective strategies in core business execution and R&D innovation.
- Strong Salix Performance: The Salix division generated $639 million in revenue, with Xifaxan showing a remarkable 21% year-over-year growth in IBS-D and OHE markets, enhancing the company's competitive position in the gastrointestinal drug sector and increasing market share.
- Solta's Success in China: Solta Medical achieved $171 million in revenue, with a staggering 193% year-over-year growth in China, indicating strong post-integration demand and solidifying the company's leadership in the global market.
- 2026 Outlook: The company reaffirmed its 2026 revenue guidance between $5.250 billion and $5.400 billion, with adjusted EBITDA projected between $2.875 billion and $2.950 billion, showing optimism despite the anticipated impact of new tariffs, reflecting a proactive approach to market changes.
See More
Bausch Health Reports Strong Q1 2026 Performance
- Revenue Growth: Bausch Health reported Q1 2026 revenue of $2.524 billion, a 12% increase year-over-year, driven primarily by strong performances from Salix and Solta, reflecting robust execution in core business and sustained market demand.
- Significant EBITDA Increase: Adjusted EBITDA rose to $837 million, a 27% year-over-year increase, largely attributed to improved profitability in Salix and Solta, showcasing the company's success in optimizing capital structure and enhancing operational efficiency.
- Healthy Cash Flow: The first quarter adjusted operating cash flow was $374 million, nearly $200 million higher than the previous year, indicating ongoing progress in cash generation and capital allocation flexibility.
- Advancements in R&D and Business Development: Bausch Health made significant strides in advancing the Phase III program for larsucosterol, demonstrating strategic commitment to addressing unmet medical needs while continuing to assess multiple business development opportunities to strengthen its R&D pipeline.
See More
Bausch Health (BHC) Q1 2026 Earnings Transcript
See More
Bausch Health Companies Exceeds Expectations in Earnings Report
- Strong Earnings Report: Bausch Health Companies saw its shares rise in after-hours trading as it reported a Q1 non-GAAP EPS of $0.78, beating expectations by $0.09, indicating a significant improvement in profitability.
- Revenue Growth: The company achieved a 9% year-over-year revenue increase to approximately $2.5 billion in Q1, surpassing market expectations of $2.41 billion, demonstrating its sustained competitive strength in the market.
- 2026 Revenue Guidance: Bausch Health projects full-year revenue for 2026 in the range of $10.67 billion to $10.92 billion, aligning with the consensus estimate of $10.68 billion, reflecting management's confidence in future performance.
- Stable Cash Flow: As of March 31, 2025, the company reported cash and cash equivalents of approximately $1.3 billion, consistent with the December 31, 2025 level, highlighting effective liquidity management.
See More
Bausch Health Companies Reports Strong Q1 Earnings, Exceeds Estimates
- Significant Revenue Growth: Bausch Health Companies reported Q1 revenue of $2.52 billion, a 12% year-over-year increase, primarily driven by its Bausch + Lomb eyecare segment, which generated $1.24 billion, reflecting a 9% gain.
- Substantial Net Income Increase: The company's non-GAAP net income surged by 35% to $296 million, translating to $0.78 per share, surpassing analyst expectations of $0.68, indicating enhanced profitability.
- Consistent Growth Indicator: Bausch has achieved 12 consecutive quarters of year-over-year revenue growth, demonstrating stability and execution within its operations, despite its somewhat sprawling business structure.
- 2026 Financial Outlook: The company maintained its full-year 2026 revenue guidance of $10.67 billion to $10.92 billion, with adjusted EBITDA expected to be between $3.89 billion and $4.01 billion, reflecting confidence in future growth.
See More
Bausch Health Beats Q1 Estimates with Strong Revenue Growth
- Significant Revenue Growth: Bausch Health reported Q1 revenue of $2.52 billion, a 12% year-over-year increase that surpassed analyst expectations of $2.42 billion, driven primarily by a strong performance in its Bausch + Lomb eyecare segment, which contributed a 9% gain.
- Substantial Net Income Increase: The company's non-GAAP net income surged by 35% to $296 million, translating to $0.78 per share, reflecting successful cost control and operational efficiency, which bolsters investor confidence in the company's financial health.
- Sustained Growth Strategy: Bausch Health has achieved 12 consecutive quarters of year-over-year revenue growth, indicating stability and execution capability despite its sprawling business structure, which may continue to attract investor interest moving forward.
- Stable Outlook: The company maintained its full-year 2026 revenue guidance of $10.67 billion to $10.92 billion, with adjusted EBITDA expected to be between $3.89 billion and $4.01 billion, demonstrating management's confidence in future performance, although no profitability guidance was provided.
See More
Bausch Health Reports Strong Q1 2026 Earnings with Reaffirmed Guidance
- Consistent Growth: Bausch Health reported Q1 2026 revenue of $2.524 billion, a 12% year-over-year increase, with adjusted EBITDA at $837 million, demonstrating a robust performance across 12 consecutive quarters, reflecting effective strategies in core business execution and R&D innovation.
- Strong Salix Performance: The Salix division generated $639 million in revenue, with Xifaxan showing a remarkable 21% year-over-year growth in IBS-D and OHE markets, enhancing the company's competitive position in the gastrointestinal drug sector and increasing market share.
- Solta's Success in China: Solta Medical achieved $171 million in revenue, with a staggering 193% year-over-year growth in China, indicating strong post-integration demand and solidifying the company's leadership in the global market.
- 2026 Outlook: The company reaffirmed its 2026 revenue guidance between $5.250 billion and $5.400 billion, with adjusted EBITDA projected between $2.875 billion and $2.950 billion, showing optimism despite the anticipated impact of new tariffs, reflecting a proactive approach to market changes.
See More
Bausch Health Reports Strong Q1 2026 Performance
- Revenue Growth: Bausch Health reported Q1 2026 revenue of $2.524 billion, a 12% increase year-over-year, driven primarily by strong performances from Salix and Solta, reflecting robust execution in core business and sustained market demand.
- Significant EBITDA Increase: Adjusted EBITDA rose to $837 million, a 27% year-over-year increase, largely attributed to improved profitability in Salix and Solta, showcasing the company's success in optimizing capital structure and enhancing operational efficiency.
- Healthy Cash Flow: The first quarter adjusted operating cash flow was $374 million, nearly $200 million higher than the previous year, indicating ongoing progress in cash generation and capital allocation flexibility.
- Advancements in R&D and Business Development: Bausch Health made significant strides in advancing the Phase III program for larsucosterol, demonstrating strategic commitment to addressing unmet medical needs while continuing to assess multiple business development opportunities to strengthen its R&D pipeline.
See More
Bausch Health (BHC) Q1 2026 Earnings Transcript
See More
Bausch Health Companies Exceeds Expectations in Earnings Report
- Strong Earnings Report: Bausch Health Companies saw its shares rise in after-hours trading as it reported a Q1 non-GAAP EPS of $0.78, beating expectations by $0.09, indicating a significant improvement in profitability.
- Revenue Growth: The company achieved a 9% year-over-year revenue increase to approximately $2.5 billion in Q1, surpassing market expectations of $2.41 billion, demonstrating its sustained competitive strength in the market.
- 2026 Revenue Guidance: Bausch Health projects full-year revenue for 2026 in the range of $10.67 billion to $10.92 billion, aligning with the consensus estimate of $10.68 billion, reflecting management's confidence in future performance.
- Stable Cash Flow: As of March 31, 2025, the company reported cash and cash equivalents of approximately $1.3 billion, consistent with the December 31, 2025 level, highlighting effective liquidity management.
See More
